Brain metastases in HER2-positive breast cancer
A partir de données portant sur 3 041 patientes atteintes d'un cancer du sein HER2+ et incluses dans l'essai HERA, cette étude rétrospective évalue l'association entre un traitement adjuvant au trastuzumab et le risque d'une récidive localisée dans le système nerveux central
HER2 overexpression is a risk factor for CNS metastases in patients with breast cancer. Between 30% and 55% of patients with metastatic, HER2-positive disease will develop brain metastases with time. Most HER2-directed therapies do not adequately penetrate the CNS, and evidence suggests that isolated CNS progression still occurs with the newest treatments, including trastuzumab emtansine.
The HERA trial is a phase 3 study comparing adjuvant trastuzumab for 1 year or 2 years with observation after standard adjuvant chemotherapy. In The Lancet Oncology, Bernhard Pestalozzi and colleagues report a CNS-specific analysis of patients in the group given 1 year of trastuzumab and in the observation group. They retrospectively gathered information about subsequent CNS recurrence with a data collection form that was circulated to investigators to obtain data for patients who had died...
The Lancet Oncology , commentaire en libre accès, 2012